Health & Biotech
Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, as well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and a lack of cardiotoxicity.
Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML), exploring anti-cancer plus cardio-protection in synergy with known standards of care.
As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of cancers.
Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Which ASX companies are resurrecting abandoned drugs? Part 3
Health & Biotech
Which ASX companies are resurrecting abandoned drugs? Part 2
Health & Biotech
Which ASX companies are resurrecting abandoned drugs? Part 1
Stockhead TV
WTF with Race Oncology: Changing the chemo game
Health & Biotech
ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors
Health & Biotech
Race Oncology achieves ‘major milestone’ in progress of lead drug to human trials
Health & Biotech
ASX health stocks: Proteomics tumbles 22pc on delayed product launch, Race hits 10mth highs
Health & Biotech
International cardiometabolic expert to join Race Oncology’s scientific advisory board
News
Market Highlights: Wall Street’s mixed as oil rises, copper flies and the crunch comes for iron ore
Health & Biotech
‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 1
Health & Biotech
ASX Health Stocks: Atomo pops 90pc after purchase order; AdAlta up 20pc on Phase 1 results
Health & Biotech
These ASX biotechs want to tackle cancer head-on for better outcomes
Health & Biotech
‘Significant potential’: This ASX stock is winning the race to make cancer care heart-safe
Health & Biotech
Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again
Stockhead TV
What’s in Store for 2024: Race Oncology
News
ASX Quarterly Wrap: HTG sales momentum continues, Race Oncology appoints CEO
News